From the Department of Radiology, University of Texas MD Anderson Cancer Center, 1400 Pressler St, Unit 1482, Houston, TX 77030 (R.R.C., J.W., S.K.S., P.O.Z.); Department of Biomedical Informatics, Emory University, Atlanta, Ga (D.A.G.); and Department of Neurosurgery, Baylor College of Medicine, Houston, Tex (P.O.Z.).
Radiology. 2015 Apr;275(1):215-27. doi: 10.1148/radiol.14141800. Epub 2014 Dec 5.
To identify the molecular profiles of cell death as defined by necrosis volumes at magnetic resonance (MR) imaging and uncover sex-specific molecular signatures potentially driving oncogenesis and cell death in glioblastoma (GBM).
This retrospective study was HIPAA compliant and had institutional review board approval, with waiver of the need to obtain informed consent. The molecular profiles for 99 patients (30 female patients, 69 male patients) were identified from the Cancer Genome Atlas, and quantitative MR imaging data were obtained from the Cancer Imaging Archive. Volumes of necrosis at MR imaging were extracted. Differential gene expression profiles were obtained in those patients (including male and female patients separately) with high versus low MR imaging volumes of tumor necrosis. Ingenuity Pathway Analysis was used for messenger RNA-microRNA interaction analysis. A histopathologic data set (n = 368; 144 female patients, 224 male patients) was used to validate the MR imaging findings by assessing the amount of cell death. A connectivity map was used to identify therapeutic agents potentially targeting sex-specific cell death in GBM.
Female patients showed significantly lower volumes of necrosis at MR imaging than male patients (6821 vs 11 050 mm(3), P = .03). Female patients, unlike male patients, with high volumes of necrosis at imaging had significantly shorter survival (6.5 vs 14.5 months, P = .01). Transcription factor analysis suggested that cell death in female patients with GBM is associated with MYC, while that in male patients is associated with TP53 activity. Additionally, a group of therapeutic agents that can potentially be tested to target cell death in a sex-specific manner was identified.
The results of this study suggest that cell death in GBM may be driven by sex-specific molecular pathways.
通过磁共振成像(MR)上的坏死体积来确定细胞死亡的分子特征,并揭示可能导致胶质母细胞瘤(GBM)发生和细胞死亡的性别特异性分子特征。
本回顾性研究符合 HIPAA 规定,并经机构审查委员会批准,豁免了获得知情同意的要求。从癌症基因组图谱(Cancer Genome Atlas)中确定了 99 名患者(30 名女性患者,69 名男性患者)的分子特征,并从癌症成像档案(Cancer Imaging Archive)中获得了定量 MR 成像数据。提取了 MR 成像上的坏死体积。在那些肿瘤坏死的 MR 成像体积高与低的患者中(包括男性和女性患者分别),获得了差异基因表达谱。使用通路分析工具(Ingenuity Pathway Analysis)进行信使 RNA-微小 RNA 相互作用分析。使用组织病理学数据集(n=368;144 名女性患者,224 名男性患者)通过评估细胞死亡的数量来验证 MR 成像结果。使用连接图谱(connectivity map)来识别可能靶向 GBM 中性别特异性细胞死亡的治疗药物。
女性患者的 MR 成像上的坏死体积明显低于男性患者(6821 比 11050mm³,P=0.03)。与男性患者不同,女性患者的成像上有高体积的坏死与较短的生存时间相关(6.5 比 14.5 个月,P=0.01)。转录因子分析表明,女性 GBM 患者的细胞死亡与 MYC 相关,而男性患者的细胞死亡与 TP53 活性相关。此外,还确定了一组可能以性别特异性方式针对细胞死亡进行测试的治疗药物。
本研究结果表明,GBM 中的细胞死亡可能是由性别特异性的分子途径驱动的。